Log In
BCIQ
Print this Print this
 

PN2034

  Manage Alerts
Collapse Summary General Information
Company Wellstat Therapeutics Corp.
DescriptionOral insulin sensitizer
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase II
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
PartnerSanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$350.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/26/2009

$350.0M

Undisclosed

Undisclosed

Get a free BioCentury trial today